Biora Therapeutics Q2 EPS $(1.47) Beats $(1.60) Estimate, Sales $2.00K Miss $20.00K Estimate
Portfolio Pulse from vinayak@benzinga.com
Biora Therapeutics reported Q2 losses of $(1.47) per share, beating the analyst consensus estimate of $(1.60) by 8.13%. However, the company's quarterly sales of $2.00K missed the estimate of $20.00K by 90.00%. This represents a 96% decrease in EPS and a 98.08% decrease in sales compared to the same period last year.
August 14, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biora Therapeutics' Q2 results beat EPS estimates but missed on sales. This could lead to mixed reactions in the market.
While Biora Therapeutics beat EPS estimates, which is generally a positive signal, the significant miss on sales could offset this positive sentiment. The drastic decrease in both EPS and sales compared to the same period last year could also negatively impact investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100